武田藥品2024年第三季度GAAP每股收益為15.01日元，同比下降67.38日元，銷售額為1.144萬億日元，超出預期1.139萬億日元

財報速遞

01/30

武田藥品 (NYSE:TAK) 報告季度每股收益為15.01日元。這較去年同期的每股收益67.38日元下降了77.72%。公司報告季度銷售額為1.144萬億日元，超出分析師一致預期的1.139萬億日元，超出0.42%。這較去年同期的1.111萬億日元銷售額增長了2.97%。

以上內容來自Benzinga Earnings專欄，原文如下：

Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of ¥15.01 per share. This is a 77.72 percent decrease over earnings of ¥67.38 per share from the same period last year. The company reported quarterly sales of ¥1.144 trillion which beat the analyst consensus estimate of ¥1.139 trillion by 0.42 percent. This is a 2.97 percent increase over sales of ¥1.111 trillion the same period last year.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1118495484"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118495484\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118495484?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-01-30 14:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118495484","market":"us","top_or_hot":-1,"title":"武田藥品2024年第三季度GAAP每股收益為15.01日元，同比下降67.38日元，銷售額為1.144萬億日元，超出預期1.139萬億日元","media":"財報速遞","content":"武田藥品 (NYSE:TAK) 報告季度每股收益為15.01日元。這較去年同期的每股收益67.38日元下降了77.72%。公司報告季度銷售額為1.144萬億日元，超出分析師一致預期的1.139萬億日元，超出0.42%。這較去年同期的1.111萬億日元銷售額增長了2.97%。<br><br>以上內容來自Benzinga Earnings專欄，原文如下：<br><html><body><p>Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of ¥15.01 per share. This is a 77.72 percent decrease over earnings of ¥67.38 per share from the same period last year. The company reported quarterly sales of ¥1.144 trillion which beat the analyst consensus estimate of ¥1.139 trillion by 0.42 percent. This is a 2.97 percent increase over sales of ¥1.111 trillion the same period last year.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>武田藥品2024年第三季度GAAP每股收益為15.01日元，同比下降67.38日元，銷售額為1.144萬億日元，超出預期1.139萬億日元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n武田藥品2024年第三季度GAAP每股收益為15.01日元，同比下降67.38日元，銷售額為1.144萬億日元，超出預期1.139萬億日元\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1048278264\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/decf3d8a922fc5c1c1d787bf8b36173f);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">財報速遞 </p>\n<p class=\"h-time smaller\">2025-01-30 14:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n武田藥品 (NYSE:TAK) 報告季度每股收益為15.01日元。這較去年同期的每股收益67.38日元下降了77.72%。公司報告季度銷售額為1.144萬億日元，超出分析師一致預期的1.139萬億日元，超出0.42%。這較去年同期的1.111萬億日元銷售額增長了2.97%。<br><br>以上內容來自Benzinga Earnings專欄，原文如下：<br><html><body><p>Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of ¥15.01 per share. This is a 77.72 percent decrease over earnings of ¥67.38 per share from the same period last year. The company reported quarterly sales of ¥1.144 trillion which beat the analyst consensus estimate of ¥1.139 trillion by 0.42 percent. This is a 2.97 percent increase over sales of ¥1.111 trillion the same period last year.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TAK","symbol_name":"武田製藥","start_time":0,"source_url":"","article_id":"1118495484","we_media_id":"1048278264","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118495484","pubTimestamp":1738220174,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"財報速遞","introduction":"每日财报追踪","home_visible":1,"id":"1048278264","head_image":"https://community-static.tradeup.com/news/decf3d8a922fc5c1c1d787bf8b36173f"},"summary":"武田藥品  報告季度每股收益為15.01日元。這較去年同期的每股收益67.38日元下降了77.72%。公司報告季度銷售額為1.144萬億日元，超出分析師一致預期的1.139萬億日元，超出0.42%。以上內容來自Benzinga Earnings專欄，原文如下：Takeda Pharmaceutical  reported quarterly earnings of 15.01 per share. This is a 77.72 percent decrease over earnings of 67.38 per share from the same period last year. The company reported quarterly sales of 1.144 trillion which beat the analyst consensus estimate of 1.139 trillion by 0.42 percent. This is a 2.97 percent increase over sales of 1.111 trillion the same","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"TAK":"武田制药"},"translate_title":"Takeda Pharmaceuticals Q3 2024 GAAP EPS of JPY 15.01, down JPY 67.38 YY, sales of JPY 1.144 trillion beat expectations of JPY 1.139 trillion","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":0.9},"content_text":"武田藥品 (NYSE:TAK) 報告季度每股收益為15.01日元。這較去年同期的每股收益67.38日元下降了77.72%。公司報告季度銷售額為1.144萬億日元，超出分析師一致預期的1.139萬億日元，超出0.42%。這較去年同期的1.111萬億日元銷售額增長了2.97%。以上內容來自Benzinga Earnings專欄，原文如下：Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of ¥15.01 per share. This is a 77.72 percent decrease over earnings of ¥67.38 per share from the same period last year. The company reported quarterly sales of ¥1.144 trillion which beat the analyst consensus estimate of ¥1.139 trillion by 0.42 percent. This is a 2.97 percent increase over sales of ¥1.111 trillion the same period last year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}